Re CDY it's not just the China distribution ann IMHO but rather where the balance sheet and income statement seem to be heading.
Assuming say $2m+ revenue and $2m operating expenses (before R&D rebate is counted) what is such a company worth on just the known knowns? $20m, $40m , $60m? There is a projection that CXBladder royalties will reach $2m p.a. alone in 2 or 3 years.
Expectations and corresponding price spikes go lot further of course (as they to with all of the biotechs). In additiom there are additional licensed assays coming very close to market.
I do realise MC just reflects sentiment on the day so there will be fun and games to be had along the way it seems :-)
